Welcome to our dedicated page for Q32 BIO SEC filings (Ticker: QTTB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Q32 Bio Inc. (QTTB) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K that highlight material events. Q32 Bio’s filings reflect its status as a Nasdaq-listed clinical stage biotechnology company focused on alopecia areata and other autoimmune and inflammatory diseases.
Recent Form 8-K filings referenced by Q32 Bio include reports furnished under Item 2.02 for quarterly financial results and corporate updates, and under Item 8.01 for other events such as clinical trial milestones. For example, the company has filed 8-Ks in connection with press releases announcing financial results for specific quarters, as well as an 8-K describing the completion of enrollment in Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart for alopecia areata. Another 8-K details leadership changes under Item 5.02, including the resignation of a Chief Medical Officer and the appointment of an interim Chief Medical Officer.
Q32 Bio’s 8-K filings also confirm that its common stock, with a par value of $0.0001 per share, is registered pursuant to Section 12(b) of the Exchange Act and trades on Nasdaq under the symbol QTTB. The filings typically attach press releases as exhibits, which are incorporated by reference where specified, and clarify whether the information is being furnished rather than filed for purposes of Section 18 of the Exchange Act.
On Stock Titan, these SEC documents are updated as they become available from EDGAR and are paired with AI-powered summaries that explain the key points in accessible language. Users can quickly see which filings relate to financial results, clinical trial updates, leadership changes, or other corporate events, and can review the underlying forms and exhibits for more detail.
Q32 Bio Inc. entered into a Controlled Equity Sales Agreement with Cantor Fitzgerald & Co. to establish an at-the-market stock offering program. Under this agreement, Q32 Bio may sell shares of its common stock from time to time, with an aggregate offering price of up to $14,200,000.
The shares will be issued under an effective Form S-3 shelf registration and a related prospectus supplement. Q32 Bio will control key sale parameters and is not obligated to sell any shares. Cantor Fitzgerald will act as sales agent on a commercially reasonable efforts basis and receive a 3.0% cash commission on gross proceeds.
Q32 Bio Inc. is offering up to $14,200,000 of Common Stock through an at-the-market sales agreement with Cantor Fitzgerald & Co.
The company may sell shares from time to time under the sales agreement, with Cantor acting as sales agent or principal and receiving a 3.0% commission on gross proceeds. Sales are intended to be conducted as an at the market offering and are subject to the terms of the sales agreement. The prospectus supplement cites a March 26, 2026 last reported sale price of $7.14 per share and discloses a public float calculation used to limit offerings under Form S-3 General Instruction I.B.6.
Violette Shelia M. reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. Chief Scientific Officer Shelia M. Violette received a grant of 37,500 restricted stock units on February 24, 2026, at no cash cost per unit. The RSUs vest in four equal installments: 25% after 6 months from the grant date and 25% after 12, 24, and 36 months, with each RSU representing one share of common stock.
After this award, she directly holds 93,069 common shares. She is also a manager of Violette Holdings LLC, which holds 36,277 common shares; she disclaims beneficial ownership of those indirect shares except to the extent of her pecuniary interest.
Morrison Jodie Pope reported acquisition or exercise transactions in this Form 4 filing.
Q32 Bio Inc. reported that CEO and director Jodie Pope Morrison received a grant of 132,000 shares of Common Stock on February 24, 2026 at a price of $0.0000 per share. Following this award, her directly held Common Stock position is 221,104 shares.
The award is structured as restricted stock units (RSUs). The RSUs vest in four equal 25% installments: 6, 12, 24, and 36 months from the February 24, 2026 grant date. Each RSU represents a contingent right to receive one share of Q32 Bio common stock as it vests.
Q32 Bio Inc. reported that its CFO and President, Lee Kalowski, received an equity award of 53,250 shares of common stock in the form of restricted stock units. This is a compensation-related grant at a price of $0.00 per share, not an open‑market purchase.
The RSUs vest in four equal 25% installments starting six months after the February 24, 2026 grant date, then at 12, 24, and 36 months from that date. Each RSU converts into one share of common stock upon vesting. After this grant, Kalowski holds 89,193 shares directly.
OrbiMed Advisors LLC and OrbiMed Capital GP VII LLC filed Amendment No. 1 to their Schedule 13D on Q32 Bio Inc., reporting beneficial ownership of 2,252,987 shares of common stock, or 15.4% of the outstanding shares.
The filing explains that their ownership percentage decreased by more than 1% because Q32 Bio’s total shares outstanding increased, not because OrbiMed changed its share count. The 15.4% figure is based on 14,629,463 shares outstanding as set forth in Q32 Bio’s Form 10‑K filed on March 1, 2026.
The shares are held by OrbiMed Private Investments VII, LP, with OrbiMed GP as its general partner and OrbiMed Advisors as managing member, giving them shared voting and dispositive power. OrbiMed indicates it may buy or sell Q32 Bio shares in the future depending on company performance, market conditions and other factors, but states it has no current plans for corporate control actions such as mergers, board changes or major asset sales.
Q32 Bio Inc. is a clinical-stage biotechnology company focused on restoring healthy immune balance, led by its antibody bempikibart for alopecia areata and other autoimmune diseases. Bempikibart blocks IL‑7 and TSLP signaling and has completed two Phase 2a trials in alopecia areata and atopic dermatitis with a favorable safety profile and biomarker changes consistent with its mechanism. The ongoing SIGNAL‑AA Part B Phase 2a trial in severe and very severe alopecia areata has enrolled 33 patients for 36 weeks of treatment, with 36‑week topline data expected in mid‑2026, and the FDA has granted Fast Track designation for alopecia areata. Q32 sold its Phase 2 complement asset ADX‑097 to Akebia Therapeutics, receiving a $7.0 million upfront payment, a $3.0 million payment at six months, a $2.0 million near‑term milestone and eligibility for up to $580 million in additional milestones plus tiered royalties. The company retains its tissue‑targeted complement platform, including ADX‑096, and holds or licenses intellectual property expected to protect bempikibart compositions to 2040 and methods of use to 2044.
Q32 Bio Inc. reported a sharp turnaround to profitability for the quarter and year ended December 31, 2025, driven by collaboration revenue and an asset sale. Quarterly collaboration arrangement revenue was $53.7 million, supporting net income of $57.7 million, or $4.60 basic earnings per share, versus a net loss in the prior-year quarter.
For full-year 2025, Q32 Bio generated net income of $29.8 million, or $2.42 basic earnings per share, compared with a $47.7 million net loss in 2024. The swing was primarily due to non-cash collaboration revenue recognized under the amended Amgen agreement and the gain on sale of ADX‑097 to Akebia Therapeutics.
Cash and cash equivalents were $48.3 million as of December 31, 2025. Combined with gross proceeds from a $10.5 million registered direct offering completed in February 2026 and guaranteed near-term milestone payments from the ADX‑097 sale, the company expects funding to last into the fourth quarter of 2027.
Operationally, Q32 Bio completed enrollment in Part B of its SIGNAL‑AA Phase 2a trial of bempikibart in severe alopecia areata, expanding to 33 patients, with a 36‑week topline data readout anticipated in mid‑2026. An open-label extension from Part A remains ongoing to assess longer-term outcomes.
Q32 Bio Inc. executive Lee Kalowski, the CFO and President, reported an automatic sale of 3,995 shares of common stock on February 25, 2026 to cover tax withholding tied to vesting of restricted stock units. The weighted average sale price was $4.5144 per share, with individual trades ranging from $4.35 to $4.69. After these transactions, Kalowski directly owned 35,943 shares of Q32 Bio common stock.
Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an open-market sale of 9,896 shares of common stock on February 25, 2026 at a weighted average price of $4.5144 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations related to the vesting of restricted stock units, and the sales were automatic and not at her discretion. The trades occurred in multiple transactions at prices ranging from $4.35 to $4.69 per share. After these sales, she directly owned 89,104 Q32 Bio shares.